Frazier Life Sciences Funds Buy $2.3M of NewAmsterdam Pharma Stock
NAMS is trading near its 52-week low of $21.02 (11% above the low) on elevated volume (2.2× avg).
Summary
Frazier Life Sciences funds bought $2.3M of NewAmsterdam Pharma stock in September 2026, increasing their stake to 6.1%.
Key Events · Ownership and Investor Activity · NAMS
-
Frazier Funds Buy $2.3M in Shares
Frazier Life Sciences Public Fund, XI, and XII purchased approximately $2.3 million of NewAmsterdam Pharma shares across 12 trading days in September 2026, at prices ranging from $21.08 to $25.50.
-
Stake Increases to 6.1%
The purchases increase Frazier Life Sciences X, L.P.'s beneficial ownership to 7,329,857 shares (6.1% of outstanding), with the broader Frazier group holding approximately 18.2% collectively.
-
Purchases Follow EU Approval
The buying occurred after the European Commission granted marketing authorization for obicetrapib monotherapy and its fixed-dose combination on September 21, 2026.
-
Institutional Conviction
Frazier Life Sciences is a dedicated life sciences venture capital firm, and these open-market purchases represent a meaningful capital commitment to NewAmsterdam Pharma's commercial launch.
Analysis · NAMS · Life Sciences
Frazier Life Sciences funds purchased approximately $2.3 million of NewAmsterdam Pharma shares across multiple transactions in September 2026, at prices ranging from $21.08 to $25.50. This is a significant accumulation by a major life sciences investor, adding to their existing 6.1% stake in the company. The purchases come just days after the European Commission granted marketing authorization for obicetrapib, suggesting institutional confidence in the company's commercial prospects.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAMS was trading at $23.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $21.02 to $42.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.